nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2025
0mins
Should l Buy HIMS?
Source: Benzinga
U.S. Stock Market Update: U.S. stock futures are down, with notable declines in pre-market trading for several companies, including nCino, Inc. which fell 31.5% after reporting weaker-than-expected earnings.
Significant Stock Movements: Other stocks experiencing sharp declines include Jayud Global Logistics (-78.3%), Waton Financial (-28%), and Newsmax (-21.2%), following previous gains, while Tesla's shares dropped 2.4% amid ongoing sales challenges in Europe.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 15.800
Low
16.50
Averages
32.95
High
60.00
Current: 15.800
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Dynamics of Heavily Shorted Stocks
- Attraction of Shorted Stocks: LCID stock has become a target for heavy shorting as many experienced traders and institutional investors believe the company's fundamentals are overvalued, reflecting a pessimistic outlook on its future performance.
- Short Selling Mechanics: Short sellers bet on significant risks facing the company, such as poor earnings or industry headwinds, which may lead to a decline in stock price, thus garnering attention for short-selling strategies in the market.
- Short Squeeze Dynamics: When a stock's price unexpectedly rises, short sellers are forced to buy back shares to cover their positions, creating a surge in demand that further drives up the price, resulting in a feedback loop that can lead to explosive gains in a short time frame.
- Most Shorted Stocks List: As of February 13, the most heavily shorted stocks include companies with market caps above $2 billion and free floats exceeding 5 million shares, with short interest serving as a barometer of market sentiment.
See More
Hims & Hers Shares Plunge Amid Novo Nordisk Lawsuit
- Stock Price Plunge: Hims & Hers Health (HIMS) shares fell approximately 16% on Monday following a lawsuit from Novo Nordisk (NVO), indicating market concerns over legal uncertainties and investment risks surrounding the company.
- Surge in Short Interest: As of February 11, short interest in HIMS reached a new 52-week high of 77.5 million shares, representing 37% of the float, reflecting a growing pessimism among investors regarding the company's outlook.
- Legal Challenge Impact: Novo Nordisk's lawsuit alleges that HIMS violated key patents related to its weight loss drug Wegovy, prompting HIMS to withdraw its copycat version amid regulatory scrutiny, which has further unsettled the market.
- Market Volatility Expectations: According to S3 Partners, HIMS is projected to experience a one-day price move of +/-14% following its Q4 2025 results scheduled for February 23, highlighting the high uncertainty surrounding the company's future performance.
See More
Novo Nordisk Launches Wegovy in Vials to Compete
- Intensifying Market Competition: Novo Nordisk plans to launch its Wegovy drug in vials to counteract pressure from rival Eli Lilly in the rapidly growing weight-loss market, especially after Lilly's introduction of vials for Zepbound in 2024 led to a surge in demand and shortages of its injector pens.
- Flexible Dosing Advantage: The new vial format will offer more flexible dosing compared to prefilled injector pens, although patients will need to manually draw the medication into a syringe, a change aimed at meeting the broader needs of obesity patients and aligning with Novo Nordisk's long-term strategic goals.
- Sales Outlook Downgrade: Novo Nordisk expects adjusted sales growth for 2026 to decline by 5% to 13%, primarily due to the impact of the U.S. “Most Favored Nations” agreement and the expiration of the semaglutide molecule patent in certain international markets, which will negatively affect the company's future revenue.
- Legal Action Update: Novo Nordisk recently filed a lawsuit against Hims & Hers, demonstrating the company's proactive stance in protecting its market share and intellectual property, even as its stock price fell by 0.82% to $48.34 at the time of publication, reflecting market concerns about its future performance.
See More
Novo Nordisk Aims for 15 Million New Patients with Medicare Coverage
- Medicare Coverage Goal: CEO Mike Doustdar of Novo Nordisk stated that the company aims to reach about 15 million new patients once Medicare begins covering obesity treatments, although he cautioned that the expansion of coverage is unlikely to happen quickly, indicating challenges in market adoption.
- Significant Price Reductions: Wegovy pills are listed at $149 on the newly launched TrumpRx website, representing an approximately 89% discount from prevailing market prices, while Wegovy and Ozempic pens start at $199, showcasing Novo Nordisk's strategic pricing adjustments in a competitive landscape.
- Increased Competitive Pressure: In contrast, Eli Lilly expects revenues of $80–$83 billion, exceeding Wall Street's forecast of $77.62 billion, indicating strong market performance, which puts pressure on Novo Nordisk to implement strategies to close the gap.
- Stock Price Volatility: Over the past year, Novo Nordisk's stock has declined by 40.41%, closing at $48.74, reflecting market concerns regarding its future growth prospects, particularly amid intensifying competition.
See More
Novo Nordisk Faces Market Challenges and Opportunities
- Market Share Risk: Novo Nordisk's forecast for 2026 indicates potential sales and profit declines of up to 13%, starkly contrasting with Eli Lilly's projected 25% growth, highlighting increasing pressure on the company in the weight loss drug market that could undermine investor confidence.
- Patent Lawsuit and Regulatory Warning: Novo has filed a patent infringement lawsuit against Hims & Hers and received a warning from the FDA regarding misleading advertising, which not only increases legal risks but may also impact the company's brand image and market strategy.
- Patient Growth and New Drug Launch: Despite challenges, Novo's Wegovy drug has attracted 246,000 patients since its January launch, indicating strong market demand that is expected to help the company regain some market share amid competition.
- Future Treatment Options: Novo plans to introduce a higher dose of Wegovy and the next-generation drug CagriSema, which has shown a potential 23% weight loss in clinical trials, potentially aiding the company in reshaping its market position in the future.
See More
Financial Firms Hit Hard by AI Tax Tool Competition
- AI Tax Tool Impact: Altruist's new Hazel AI tax planning tool can analyze 1040 forms, pay, and account statements in minutes, significantly enhancing advisor efficiency, which led to LPL Financial and Charles Schwab shares dropping 8.3% and 7.4% respectively, highlighting the pressure traditional financial services face from AI competition.
- Cloudflare's Strong Performance: Following its 2022 recommendation, Cloudflare reported a 34% year-over-year revenue increase in Q4, with annual contract value growing nearly 50%, and forecasts close to $2.8 billion in revenue for 2026, resulting in a 14% stock price increase in after-hours trading, indicating robust market demand and investor confidence.
- Mattel's Major Decline: Mattel's stock plummeted 30% due to disappointing Q3 results, with the CEO expressing skepticism about the return of toy manufacturing to the U.S., reflecting significant challenges and a loss of market confidence for the company.
- Moderna's Vaccine Application Rejected: The FDA rejected Moderna's application for a seasonal mRNA flu vaccine, causing a 9% drop in pre-market trading, illustrating the substantial impact of regulatory hurdles on biopharmaceutical companies.
See More
Market Dynamics of Heavily Shorted Stocks
- Attraction of Shorted Stocks: LCID stock has become a target for heavy shorting as many experienced traders and institutional investors believe the company's fundamentals are overvalued, reflecting a pessimistic outlook on its future performance.
- Short Selling Mechanics: Short sellers bet on significant risks facing the company, such as poor earnings or industry headwinds, which may lead to a decline in stock price, thus garnering attention for short-selling strategies in the market.
- Short Squeeze Dynamics: When a stock's price unexpectedly rises, short sellers are forced to buy back shares to cover their positions, creating a surge in demand that further drives up the price, resulting in a feedback loop that can lead to explosive gains in a short time frame.
- Most Shorted Stocks List: As of February 13, the most heavily shorted stocks include companies with market caps above $2 billion and free floats exceeding 5 million shares, with short interest serving as a barometer of market sentiment.
See More
Hims & Hers Shares Plunge Amid Novo Nordisk Lawsuit
- Stock Price Plunge: Hims & Hers Health (HIMS) shares fell approximately 16% on Monday following a lawsuit from Novo Nordisk (NVO), indicating market concerns over legal uncertainties and investment risks surrounding the company.
- Surge in Short Interest: As of February 11, short interest in HIMS reached a new 52-week high of 77.5 million shares, representing 37% of the float, reflecting a growing pessimism among investors regarding the company's outlook.
- Legal Challenge Impact: Novo Nordisk's lawsuit alleges that HIMS violated key patents related to its weight loss drug Wegovy, prompting HIMS to withdraw its copycat version amid regulatory scrutiny, which has further unsettled the market.
- Market Volatility Expectations: According to S3 Partners, HIMS is projected to experience a one-day price move of +/-14% following its Q4 2025 results scheduled for February 23, highlighting the high uncertainty surrounding the company's future performance.
See More
Novo Nordisk Launches Wegovy in Vials to Compete
- Intensifying Market Competition: Novo Nordisk plans to launch its Wegovy drug in vials to counteract pressure from rival Eli Lilly in the rapidly growing weight-loss market, especially after Lilly's introduction of vials for Zepbound in 2024 led to a surge in demand and shortages of its injector pens.
- Flexible Dosing Advantage: The new vial format will offer more flexible dosing compared to prefilled injector pens, although patients will need to manually draw the medication into a syringe, a change aimed at meeting the broader needs of obesity patients and aligning with Novo Nordisk's long-term strategic goals.
- Sales Outlook Downgrade: Novo Nordisk expects adjusted sales growth for 2026 to decline by 5% to 13%, primarily due to the impact of the U.S. “Most Favored Nations” agreement and the expiration of the semaglutide molecule patent in certain international markets, which will negatively affect the company's future revenue.
- Legal Action Update: Novo Nordisk recently filed a lawsuit against Hims & Hers, demonstrating the company's proactive stance in protecting its market share and intellectual property, even as its stock price fell by 0.82% to $48.34 at the time of publication, reflecting market concerns about its future performance.
See More
Novo Nordisk Aims for 15 Million New Patients with Medicare Coverage
- Medicare Coverage Goal: CEO Mike Doustdar of Novo Nordisk stated that the company aims to reach about 15 million new patients once Medicare begins covering obesity treatments, although he cautioned that the expansion of coverage is unlikely to happen quickly, indicating challenges in market adoption.
- Significant Price Reductions: Wegovy pills are listed at $149 on the newly launched TrumpRx website, representing an approximately 89% discount from prevailing market prices, while Wegovy and Ozempic pens start at $199, showcasing Novo Nordisk's strategic pricing adjustments in a competitive landscape.
- Increased Competitive Pressure: In contrast, Eli Lilly expects revenues of $80–$83 billion, exceeding Wall Street's forecast of $77.62 billion, indicating strong market performance, which puts pressure on Novo Nordisk to implement strategies to close the gap.
- Stock Price Volatility: Over the past year, Novo Nordisk's stock has declined by 40.41%, closing at $48.74, reflecting market concerns regarding its future growth prospects, particularly amid intensifying competition.
See More
Novo Nordisk Faces Market Challenges and Opportunities
- Market Share Risk: Novo Nordisk's forecast for 2026 indicates potential sales and profit declines of up to 13%, starkly contrasting with Eli Lilly's projected 25% growth, highlighting increasing pressure on the company in the weight loss drug market that could undermine investor confidence.
- Patent Lawsuit and Regulatory Warning: Novo has filed a patent infringement lawsuit against Hims & Hers and received a warning from the FDA regarding misleading advertising, which not only increases legal risks but may also impact the company's brand image and market strategy.
- Patient Growth and New Drug Launch: Despite challenges, Novo's Wegovy drug has attracted 246,000 patients since its January launch, indicating strong market demand that is expected to help the company regain some market share amid competition.
- Future Treatment Options: Novo plans to introduce a higher dose of Wegovy and the next-generation drug CagriSema, which has shown a potential 23% weight loss in clinical trials, potentially aiding the company in reshaping its market position in the future.
See More
Financial Firms Hit Hard by AI Tax Tool Competition
- AI Tax Tool Impact: Altruist's new Hazel AI tax planning tool can analyze 1040 forms, pay, and account statements in minutes, significantly enhancing advisor efficiency, which led to LPL Financial and Charles Schwab shares dropping 8.3% and 7.4% respectively, highlighting the pressure traditional financial services face from AI competition.
- Cloudflare's Strong Performance: Following its 2022 recommendation, Cloudflare reported a 34% year-over-year revenue increase in Q4, with annual contract value growing nearly 50%, and forecasts close to $2.8 billion in revenue for 2026, resulting in a 14% stock price increase in after-hours trading, indicating robust market demand and investor confidence.
- Mattel's Major Decline: Mattel's stock plummeted 30% due to disappointing Q3 results, with the CEO expressing skepticism about the return of toy manufacturing to the U.S., reflecting significant challenges and a loss of market confidence for the company.
- Moderna's Vaccine Application Rejected: The FDA rejected Moderna's application for a seasonal mRNA flu vaccine, causing a 9% drop in pre-market trading, illustrating the substantial impact of regulatory hurdles on biopharmaceutical companies.
See More
